When should cotrimoxazole (trimethoprim‑sulfamethoxazole) be used?

When to Use Cotrimoxazole (Trimethoprim-Sulfamethoxazole)

Cotrimoxazole should be used primarily for Pneumocystis jirovecii pneumonia (PCP) prophylaxis in HIV-infected patients with CD4 counts <200 cells/µL, for treatment of documented PCP, and for specific infections including toxoplasmosis, nocardiosis, and Stenotrophomonas maltophilia. 1, 2

Primary Indications for Cotrimoxazole Use

HIV-Related Opportunistic Infection Prophylaxis

• Initiate cotrimoxazole when CD4 count falls below 200 cells/µL in all HIV-infected adults and adolescents, including pregnant women, regardless of antiretroviral therapy status. 1
• Start prophylaxis immediately if the patient has oropharyngeal candidiasis or unexplained fever >100°F for ≥2 weeks, even when CD4 count is above 200 cells/µL. 1
• **Consider prophylaxis when CD4 percentage is <14%** or when there is a history of an AIDS-defining illness, even if absolute CD4 count is >200 cells/µL. 1

Preferred dosing: One double-strength tablet (160 mg TMP/800 mg SMX) once daily provides simultaneous protection against PCP, toxoplasmosis (in seropositive patients), and common bacterial respiratory infections. 1

Toxoplasmosis Prophylaxis and Treatment

• For Toxoplasma-IgG-positive patients with CD4 <100 cells/µL, the same daily double-strength cotrimoxazole tablet used for PCP prophylaxis provides adequate toxoplasmosis coverage—no additional agent is needed. 3, 4
• For acute toxoplasma encephalitis treatment, use 5 mg/kg trimethoprim plus 25 mg/kg sulfamethoxazole IV or orally twice daily for 6 weeks, assuming clinical and radiological improvement. 3
• For congenital toxoplasmosis, treatment duration is 12 months according to the American Academy of Pediatrics. 3

FDA-Approved Therapeutic Indications

• Documented Pneumocystis carinii pneumonia treatment in immunosuppressed patients. 2
• Urinary tract infections caused by susceptible E. coli, Klebsiella, Enterobacter, Morganella morganii, Proteus mirabilis, and Proteus vulgaris. 2
• Acute otitis media in pediatric patients (≥2 months old) due to susceptible Streptococcus pneumoniae or Haemophilus influenzae when cotrimoxazole offers advantages over single agents. 2
• Acute exacerbations of chronic bronchitis caused by susceptible S. pneumoniae or H. influenzae. 2
• Shigellosis (Shigella flexneri and Shigella sonnei) when antibacterial therapy is indicated. 2
• Travelers' diarrhea due to enterotoxigenic E. coli in adults. 2

Unconventional but Evidence-Supported Uses

• Stenotrophomonas maltophilia infections, where cotrimoxazole remains the drug of choice. 5
• Nocardiosis, brucellosis, and chancroid, where cotrimoxazole has demonstrated superiority over trimethoprim alone. 6
• Invasive methicillin-resistant Staphylococcus aureus (MRSA) infections, supported by retrospective and prospective studies showing good clinical outcomes. 5
• Listeria monocytogenes, Burkholderia, Coxiella burnetii, and Tropheryma whipplei infections. 5

When NOT to Use Cotrimoxazole

Absolute Contraindications

• Infants <2 months of age due to risk of kernicterus. 2
• Pregnant women at term and nursing mothers with infants <2 months old, as sulfonamides displace bilirubin from plasma proteins, causing hyperbilirubinemia and kernicterus risk. 7, 2
• Patients with documented hypersensitivity to trimethoprim or sulfonamides. 2
• Patients with megaloblastic anemia due to folate deficiency. 2

Relative Contraindications and High-Risk Situations

• Glucose-6-phosphate dehydrogenase (G6PD) deficiency, where hemolysis may occur (frequently dose-related). 2
• Severe renal insufficiency (CrCl <15 mL/min) without dose adjustment, as both components accumulate and increase toxicity risk. 2
• Severe hepatic impairment, which increases risk of adverse effects. 2
• Elderly patients on thiazide diuretics, who have increased risk of thrombocytopenia with purpura. 2
• Patients with underlying potassium metabolism disorders or on ACE inhibitors, due to risk of life-threatening hyperkalemia from the trimethoprim component. 2

Critical Monitoring Requirements

• Perform complete blood counts at least weekly during treatment to detect bone marrow suppression, particularly in elderly patients and those with preexisting folate deficiency. 3, 2
• Monitor serum potassium closely in patients with renal insufficiency, those receiving ACE inhibitors, or those with underlying potassium metabolism disorders. 2
• Ensure adequate fluid intake to prevent crystalluria and stone formation, especially with high-dose therapy. 2
• Monitor for skin rash, fever, leukopenia, and elevated aminotransferases, which occur more frequently in AIDS patients (up to 50-80% incidence) compared to non-AIDS patients. 2

When to Discontinue Prophylaxis

• Stop PCP and toxoplasmosis prophylaxis when CD4 count rises above 200 cells/µL and remains elevated for ≥3 months on effective antiretroviral therapy with virologic suppression. 1, 4
• Restart prophylaxis immediately if CD4 count falls below the original threshold (<200 cells/µL for PCP/toxoplasmosis). 4
• Do not base discontinuation on a single CD4 measurement; sustained elevation for ≥3 months is mandatory. 4

Important Clinical Pitfalls to Avoid

• Do not use cotrimoxazole for uncomplicated cystitis in regions where E. coli resistance exceeds 10-20%; fluoroquinolones are preferred in these settings. 8
• Do not use cotrimoxazole routinely for infections where trimethoprim alone is equally effective (most urinary and respiratory tract infections), as this exposes patients to unnecessary sulfonamide-related adverse effects without added benefit. 6, 9
• Do not prescribe cotrimoxazole to HIV-exposed but uninfected infants, as recent evidence shows no benefit and potential harm from antimicrobial resistance and microbiome disruption. 1
• Avoid excessive dosing in patients with normal renal function, as guideline-recommended doses (90 mg/kg/day for PCP treatment) may cause supratherapeutic exposure and toxicity. 10
• Never delay discontinuation of cotrimoxazole if severe rash, Stevens-Johnson syndrome, or significant cytopenias develop, as these can be life-threatening. 2, 9
• Do not use aerosolized pentamidine as sole prophylaxis when CD4 <100 cells/µL in Toxoplasma-seropositive patients, as it provides no toxoplasmosis coverage. 4

Special Populations

AIDS Patients

• AIDS patients have a markedly increased incidence of adverse effects (rash, fever, leukopenia, elevated transaminases) compared to non-AIDS patients, but these are generally less severe with prophylactic versus therapeutic dosing. 2
• A history of mild intolerance does not predict intolerance of subsequent prophylaxis, so rechallenge may be considered after resolution of adverse events. 2

Elderly Patients

• Use the lowest effective dose and shortest duration possible in elderly patients due to increased risk of severe adverse reactions, particularly thrombocytopenia, bone marrow suppression, and hyperkalemia. 2
• Monitor digoxin levels closely, as cotrimoxazole increases digoxin blood levels, especially in elderly patients. 2

Renal Impairment

• For CrCl <15 mL/min, reduce dose to 50 mg/kg/day divided three times daily for PCP treatment based on pharmacokinetic modeling. 10
• Avoid cotrimoxazole in severe renal dysfunction without dose adjustment, as accumulation of both components significantly increases toxicity risk, including crystalline nephropathy. 11